Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

I-Mab (IMAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503"
09/29/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates · Significant progress made year-to-date on key clinical assets: - Uliledlimab : Encouraging early results were presented at ASCO 2023 - Givastomig : Topline Phase 1 data with promising early efficacy signals, including patients with low levels of Claudin 18.2 tumor expression. Data to be presented at ESMO 2023 · Eftansomatropin alfa : Phase 3 pivotal study evaluating weekly injection of eftansomatropin alfa met the primary endpoint of annualized height velocity at week 52 and demonstrated non-inferiority to Norditropin®, administered by daily injection. A BLA filing is being planned for 2024 · Strong cash position of RMB3.0 billion as of June 30, 2023, to support execution of the Company’ s..."
07/11/2023 144 Form 144 - Report of proposed sale of securities:
07/05/2023 144 Form 144 - Report of proposed sale of securities:
07/05/2023 144 Form 144 - Report of proposed sale of securities:
07/05/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 SC 13D/A HHLR ADVISORS, LTD. reports a 8.3% stake in I-MAB
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023"
05/01/2023 144 Form 144 - Report of proposed sale of securities:
05/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 · Strategic reprioritization of the Company’ s pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus · Thirteen key clinical milestones achieved in 2022, including positive data readout for lemzoparlimab, uliledlimab, and givastomig and significant progress on eftansomatropin alfa and felzartamab. Phase 3 data readout of eftansomatropin alfa and potential biologics license applications submission expected by the end of 2023 or early 2024 · I-Mab and AbbVie continue to collaborate on the global developm..."
05/01/2023 6-K Quarterly results
05/01/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/25/2023 6-K Quarterly results
04/25/2023 6-K Quarterly results
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
03/31/2023 6-K Quarterly results
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 0% stake in I-MAB-SPONSORED ADR
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 SC 13G/A GIC Private Ltd reports a 6.3% stake in I-MAB
11/10/2022 6-K Quarterly results
09/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022",
"I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome GAITHERSBURG, MD. and SHANGHAI, China – September 13, 2022 – I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 meeting with the Center for Drug Evaluation of China’ s National Medical Products Administration , and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with azacitidine for the first-line treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome . The..."
08/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
08/16/2022 6-K Quarterly results
06/17/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/13/2022 SC 13G Infini Master Fund reports a 6.1% stake in I-MAB
05/27/2022 6-K Quarterly results
05/18/2022 6-K Quarterly results
05/05/2022 6-K Quarterly results
04/29/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/28/2022 6-K/A Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy